Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Iloprost for Lung Cancer Prevention
NCT02237183Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2015
- Primary completion
- Mar 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of iloprost in lung cancer (4 arms), sponsored by National Cancer Institute. Primary endpoint: Incidence of clinical toxicity at 90 days. Started Nov 2015; status: completed.
02
Drugs
iloprost
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT02237183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02237183.